A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 16, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NMRA SEC filings page.
This page shows Neumora Therapeutics, Inc. (NMRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Neumora remains a cash-consuming development business, while shrinking equity and rising liabilities have made its financing structure less conservative.
From FY2024 to FY2025, R&D fell12.4% and SG&A fell3.9% , yet lower reported operating expenses did not reduce cash needs. Operating cash outflow increased from$182.9M to$206.4M , showing that cash consumption is not explained by growth in those two expense lines alone.
FY2025 R&D was
The capital structure shifted materially: liabilities rose
Financial Health Signals
We do not publish a peer-relative financial health score for Neumora Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Neumora Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Neumora Therapeutics, Inc. reported a net loss of $236.9M while operations used $206.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Neumora Therapeutics, Inc. reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Neumora Therapeutics, Inc.'s EBITDA was -$33.4M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Neumora Therapeutics, Inc. reported a net loss of $34.4M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Neumora Therapeutics, Inc. earned -$0.18 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Neumora Therapeutics, Inc. held $85.7M in cash against $53.3M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Neumora Therapeutics, Inc.'s quarterly ROE was -185.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 142.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 88.9 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
Neumora Therapeutics, Inc. invested $22.6M in research and development in Q3 2026. This represents a decrease of 44.2% from the same quarter a year earlier. Against the prior quarter it is down 22.8%.
Not reported for Q3 2026.
Not reported for Q3 2026.
NMRA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $22.6M-44.2% | $29.3M-24.4% | $38.6M-26.0% | $44.7M-2.7% | $40.5M-33.2% | $38.7M-20.4% | $52.2M+14.0% | $45.9M+18.1% |
| SG&A Expenses | $10.8M-11.4% | $12.9M-15.7% | $14.3M-24.1% | $13.8M-18.8% | $12.2M-24.0% | $15.3M+0.8% | $18.8M+31.2% | $17.0M+51.4% |
| Operating Income | -$33.4Mn/m | -$42.2Mn/m | -$52.9Mn/m | -$58.5Mn/m | -$57.7Mn/m | -$54.0Mn/m | -$70.9Mn/m | -$62.9Mn/m |
| EBITDA | -$33.4Mn/m | -$42.2Mn/m | -$52.9Mn/m | -$58.5Mn/m | -$57.7Mn/m | -$54.0Mn/m | -$70.8Mn/m | -$62.8Mn/m |
| Interest Expense | $1.4M+170.0% | $1.4M+364.5% | $1.4Mn/m | N/A | $534Kn/m | $307K | $0 | N/A |
| Income Tax | $0n/m | $0-100.0% | $30K-71.4% | $0 | $0-100.0% | $25K-80.0% | $105K | N/A |
| Net Income | -$34.4Mn/m | -$43.1Mn/m | -$53.5Mn/m | -$59.5Mn/m | -$56.8Mn/m | -$52.7Mn/m | -$68.0Mn/m | -$58.8Mn/m |
| EPS (Basic) | -$0.18n/m | -$0.23n/m | -$0.30n/m | -$0.35n/m | -$0.35n/m | -$0.33n/m | -$0.42n/m | -$0.37 |
| EPS (Diluted) | -$0.18n/m | -$0.23n/m | -$0.30n/m | -$0.35n/m | -$0.35n/m | -$0.33n/m | -$0.42n/m | -$0.37 |
| Diluted Shares (Avg) | 188M+16.1% | 185M+14.5% | 180M+11.4% | N/A | 162M+1.4% | 162M+1.7% | 161M+2.2% | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
NMRA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'25Filing | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $95.0M-46.6% | $125.2M-44.0% | $153.9M-40.1% | $191.0M-39.7% | $177.8M-49.6% | $223.8M-44.7% | $256.7M-43.0% | $317.0M-36.1% |
| Current Assets | $94.7M-46.5% | $124.9M-44.0% | $153.4M-39.8% | $190.5M-39.3% | $177.1M-49.2% | $222.9M-44.0% | $254.9M-42.4% | $314.1M-34.3% |
| Cash & Equivalents | $85.7M-33.6% | $116.8M-6.2% | $147.1M+15.9% | $182.5M+28.4% | $129.1M-53.2% | $124.5M-17.4% | $126.9M-30.6% | $142.1M-62.0% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $42.5M-35.3% | $93.1M-57.9% | $122.5M-48.9% | $165.4M+106.9% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $0-100.0% |
| Total Liabilities | $76.5M+67.5% | $80.7M+97.2% | $83.2M+193.1% | $87.2M+191.5% | $45.7M+43.6% | $40.9M+76.4% | $28.4M+10.6% | $29.9M+10.3% |
| Current Liabilities | $23.2M-10.2% | $27.8M+31.3% | $30.1M+6.1% | $32.5M+8.6% | $25.8M-18.6% | $21.2M-8.5% | $28.4M+15.3% | $29.9M+19.0% |
| Non-Current Liabilities | $53.3M+168.8% | $53.0M+167.6% | $53.1Mn/m | $54.7M+248650.0% | $19.8M+35954.5% | $19.8M+22136.0% | $0-100.0% | $22K-98.9% |
| Long-Term Debt | $53.3M+172.5% | $52.9M+172.0% | $53.0M | $54.5Mn/m | $19.6M | $19.5M | N/A | $0 |
| Total Equity | $18.6M-86.0% | $44.5M-75.7% | $70.7M-69.0% | $103.9M-63.8% | $132.2M-58.8% | $182.9M-52.0% | $228.4M-46.2% | $287.1M-38.8% |
| Retained Earnings | -$1.3Bn/m | -$1.3Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.1Bn/m | -$1.1Bn/m | -$1.0Bn/m | -$947.2Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
NMRA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33.4Mn/m | -$39.5Mn/m | -$46.4Mn/m | -$48.0Mn/m | -$46.6Mn/m | -$52.4Mn/m | -$59.4Mn/m | -$50.3Mn/m |
| Depreciation & Amortization | $3K-87.0% | $7K-63.2% | $8K-94.9% | $9K-94.3% | $23K-85.3% | $19K-88.1% | $157K-0.6% | $157K-5.4% |
| Stock-Based Compensation | $6.1M+2.7% | $7.2M+0.3% | $7.4M-20.6% | N/A | $6.0M-39.9% | $7.2M-43.9% | $9.3M+26.5% | N/A |
| Investing Cash Flow | -$71K-100.1% | $0-100.0% | $71K-99.8% | $42.6Mn/m | $51.3M-67.3% | $30.4M+43.0% | $44.2Mn/m | -$98.8M-822.4% |
| Financing Cash Flow | $2.3Mn/m | $9.3M-49.7% | $10.9Mn/m | $58.8M+277.4% | -$136K-108.9% | $18.5M+595.4% | $0-100.0% | $15.6Mn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
NMRA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -185.7%-142.7pp | -96.8%-67.9pp | -75.6%-45.9pp | -57.2%-36.7pp | -42.9%-20.3pp | -28.8%-13.4pp | -29.8%-17.1pp | -20.5%+2.7pp |
| Return on Assets | -36.2%-4.3pp | -34.4%-10.8pp | -34.7%-8.3pp | -31.1%-12.6pp | -31.9%-11.3pp | -23.6%-9.0pp | -26.5%-14.5pp | -18.6%+3.4pp |
| Current Ratio | 4.08-2.8x | 4.50-6.0x | 5.09-3.9x | 5.87-4.6x | 6.85-4.1x | 10.54-6.7x | 8.98-9.0x | 10.51-8.5x |
| Debt-to-Equity | 2.87+2.7x | 1.19+1.1x | 0.75 | 0.53+0.5x | 0.15 | 0.11 | N/A | 0.00 |
| Liabilities-to-Equity | 4.12+3.8x | 1.81+1.6x | 1.18+1.1x | 0.84+0.7x | 0.35+0.2x | 0.22+0.2x | 0.12+0.1x | 0.100.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Neumora Therapeutics, Inc. NMRA | FY2025 | N/A | -$236.9M | N/A | $63.0M | — |
| PMV Pharmaceuticals, Inc PMVP | FY2025 | N/A | -$77.7M | N/A | $66.2M | — |
| Gossamer Bio, Inc. GOSS | FY2025 | $48.5M | -$170.4M | N/A | $65.6M | 49/100 |
| Tenaya Therapeutics, Inc. TNYA | FY2025 | N/A | -$90.6M | N/A | $65.3M | — |
| Rani Therapeutics Holdings, Inc. RANI | FY2025 | $1.6M | -$29.7M | N/A | $59.0M | 59/100 |
| Coya Therapeutics, Inc. COYA | FY2025 | $7.9M | -$21.2M | N/A | $69.2M | 64/100 |
Where Neumora Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Neumora Therapeutics, Inc. (NMRA) reported a net loss of $190.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $236.9M.
Neumora Therapeutics, Inc. (NMRA) had EBITDA of -$240.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Neumora Therapeutics, Inc. (NMRA) had $182.5M in cash and equivalents against $54.5M in long-term debt.
Neumora Therapeutics, Inc. (NMRA) has a return on equity of -228.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Neumora Therapeutics, Inc. (NMRA) recorded an outflow of $206.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Neumora Therapeutics, Inc. (NMRA) had $191.0M in total assets as of fiscal year 2025, including both current and long-term assets.
Neumora Therapeutics, Inc. (NMRA) invested $176.1M in research and development during fiscal year 2025.
Neumora Therapeutics, Inc. (NMRA) had a current ratio of 5.87 as of fiscal year 2025, which is generally considered healthy.
Neumora Therapeutics, Inc. (NMRA) had a debt-to-equity ratio of 0.53 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Neumora Therapeutics, Inc. (NMRA) had a liabilities-to-equity ratio of 0.84 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Neumora Therapeutics, Inc. (NMRA) had a return on assets of -124.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Neumora Therapeutics, Inc. (NMRA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $63.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Neumora Therapeutics, Inc. (NMRA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $63.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Neumora Therapeutics, Inc. (NMRA) held $182.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $206.4M over that year. Dividing the one by the other, the reported balance equals about 11 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Neumora Therapeutics, Inc. (NMRA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Neumora Therapeutics, Inc. (NMRA) reported a net loss of $236.9M while operations used $206.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Neumora Therapeutics, Inc. (NMRA) reported an operating loss of $241.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.